Jichuanjian，a famous classical formula with definite clinical efficacy in Jingyue Quanshu （《景岳全书》） by ZHANG Jing-yue in the Ming Dynasty， was included in the Catalogue of Ancient Famous Classical Formulas （The First Batch） published by the National Administration of Traditional Chinese Medicine（TCM） in 2018．By means of bibliometrics，43 relevant ancient book data were collected，including 26 ancient books of TCM. The historical origin and development，main indications and symptoms，composition and prescription，dosage，processing，and decoction and administration methods of Jichuanjian were systematically summarized to provide literature support for the development and clinical application of famous classic formulas. It was found that the main symptoms of Jichuanjian were expanded in the past dynasties from deficiency constipation， postpartum constipation， and qi stagnation recorded in the original formula to additional dryness accumulation， blood stasis， Yin constipation， infantile constipation， and lung（intestine）diseases induced by eye diseases. The applicable population of Jichuanjian was extended to children in addition to puerpera and adults，and the disease scope was extended to pediatrics， ophthalmology， and otorhinolaryngology in addition to internal medicine，gynecology and obstetrics．Although Jichuanjian was modified by doctors in the past dynasties，the compatibility of Angelicae Sinensis Radix，Achyranthis Bidentatae Radix，Cistanches Herba，Alismatis Rhizoma，Cimicifugae Rhizoma and Aurantii Fructus has been constant. The decoction and administration methods basically remained unchanged， i.e.， water decoction and administration before meals. Meanwhile， doctors in the Qing Dynasty made a lot of general comments on this formula with little controversy．

Wulingsan， a classic prescription first recorded in the Treatise on Cold Damage （Shang Han Lun） by ZHANG Zhong-jing for patients with water retention syndrome due to the disturbance of Qi transformation in bladder， has often been modified by ancient and modern doctors for the treatment of renal diseases. It produced satisfactory outcomes without inducing adverse reactions. The databases including China National Knowledge Infrastructure （CNKI）， Wanfang Data Knowledge Service Platform， and PubMed were searched for articles concerning the clinical application and pharmacological mechanism of Wulingsan in the treatment of renal diseases published by domestic and foreign scholars in recent years. The summary of the included articles revealed that Wulingsan has been widely employed for the treatment of renal edema， diabetic nephropathy， acute and chronic glomerulonephritis， nephrotic syndrome， renal insufficiency， abnormal urination， etc.， and the resulting outcomes were satisfactory. Wulingsan alone or in combination with western medicine yielded better clinical outcomes than the western medicine alone. In the exploration of its pharmacological mechanism， there existed some individual reports by Korean scholars， while Chinese scholars tended to work as a team. After years of research， each team has found that Wulingsan was superior to Wulingsan decoction in excreting water， which might be related to the absence of massive low-polarity and volatile components in the decoction that were responsible for regulating the expression of aquaporins （AQP） in kidney of saline-loaded rats. Wulingsan regulates the endocrine state of rats with kidney yang deficiency， inhibits the reabsorption of water， increases the activity of Na⁺-K⁺-ATPase， and reduces the expression of AQP 1， AQP 2， AQP 3， and AQP 4. Besides， it bi-directionally regulates the human water metabolism， which is achieved via the dual-directional regulation of purinergic P2X3 receptor expression on bladder detrusor. The efficacy of Wulingsan in treating chronic renal failure is attributed to its protection against the damaged renal tissue，structure and fanction. Hence， this paper summarized the research progress of Wulingsan in the treatment of renal diseases in recent years， aiming to provide a reference for the clinical and basic exploration of Wulingsan against renal diseases in the future.